“In 2017, the Philippines stopped a school-based dengue fever vaccination program after reports of complications and several deaths linked to the product called Dengvaxia. The French manufacturer, Sanofi Pasteur, later stated that the vaccine posed a risk to those without prior infection from one of the disease’s four stereotypes. The result was that it actually increased the risk that a child would contract a more severe form of the disease.“